Sermorelin

Drug Profile

Sermorelin

Alternative Names: Geref; Gerel; GRF 1-29; GRF(1-29)NH2; Groliberin; Growth hormone releasing factor-(1-29)amide; Human growth hormone releasing factor; human somatoliberin-(1-29) amide; Somatoliberin-(1-29) amide

Latest Information Update: 18 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Salk Institute
  • Class Growth hormone-releasing hormones; Peptide hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Discontinued Female infertility

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top